Active substanceAminocaproic acidAminocaproic acid
Similar drugsTo uncover
  • Aminocaproic acid
    solution d / infusion 
    ALIUM PFK, LLC     Russia
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
    MOSFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    Avexima Sibir, OOO     Russia
  • Aminocaproic acid-SOLOfarm
    solution d / infusion 
    GROTEKS, LLC     Russia
  • Dosage form: & nbspsolution for infusions
    Composition:

    Active substance: aminocaproic acid - 50 g;

    Excipients: sodium chloride 9 g, water for injection - up to 1 liter.

    Description:

    Colorless, clear liquid.

    Pharmacotherapeutic group:Hemostatic agent, inhibitor of fibrinolysis
    ATX: & nbsp

    B.02.A.A.01   Aminocaproic acid

    Pharmacodynamics:

    Has a hemostatic effect. It inhibits the conversion of fibrinolysin to fibrinolysin, apparently due to inhibition of the activator of this process, and also has a direct inhibitory effect on fibrinolysin; inhibits the activating action of streptokinase, urokinase and tissue kinases on fibrinolysis, neutralizes the effects of kallikrein, trypsin and hyaluronidase, reduces the permeability of capillaries. Has anti-allergic activity, improves the antitoxic function of the liver.

    With intravenous administration, the hemostatic effect is manifested after 15-20 minutes.

    Pharmacokinetics:

    The drug is quickly excreted by the kidneys - 40-60% of the administered amount after 4 hours is released unchanged. If the excretory function of the kidneys is disturbed, the concentration of aminocaproic acid in the blood increases significantly.

    Indications:

    Bleeding (hyperfibrinolysis, hypo- and afibrinogenemia).Bleeding during surgical interventions on organs rich in fibrinolysis activators (heart, brain and spinal cord, lungs, thyroid and pancreas, prostate gland), vessels in the ear, throat, nose. Diseases of internal organs with hemorrhagic syndrome. Premature detachment of the placenta, prolonged retention in the uterine cavity of the dead fetus, complicated abortion. To prevent secondary hypofibrinogenemia in massive transfusions of canned blood.

    Contraindications:

    Hypersensitivity to the drug, hypercoagulation (thrombosis, thromboembolism), propensity to thrombosis and thromboembolic diseases, cerebral circulation disorders, renal dysfunction, kidney disease with impaired excretory function, DIC-syndrome, pregnancy. Do not prescribe patients with hematuria or before the infusion of the concentrate of the prothrombin complex.

    Carefully:

    Diseases of the heart, bleeding from the upper urinary tract of unknown etiology, liver failure, arterial hypotension, valvular heart disease.

    Dosing and Administration:

    Introduced intravenously drip.

    The daily dose for adults is 5-30 g. If it is necessary to achieve a rapid effect (acute hypofibrinogenemia), intravenously drip up to 100 ml of sterile 5% solution on isotonic sodium chloride solution at a rate of 50-60 drops per minute. During the first hour, a dose of 4-5 g is administered, in the case of continuing bleeding - until it stops completely - 1 g every hour for not more than 8 hours. If necessary, administer a 5% solution of aminocaproic acid repeat.

    Children - at the rate of 100 mg / kg body weight in the first hour, then 33 mg / kg / h, the maximum daily dose of -18 g / m2 surface of the body.

    The duration of therapy is 3-14 days.

    Side effects:

    Dizziness, tinnitus, headache, nausea, diarrhea, nasal congestion, skin rash, lowering of blood pressure, orthostatic hypotension, convulsions, myoglobinuria, acute renal failure, subendocardial hemorrhage, rhabdomyolysis.

    Overdose:

    If the initiation of aminocaproic acid develops the initial signs of toxic effects, discontinue the drug and conduct symptomatic treatment.

    Interaction:

    Anticoagulants of direct and indirect action, antiaggregants decrease efficiency.You can combine with the introduction of hydrolysates, dextrose (glucose) solution, anti-shock solutions. In acute fibrinolysis, fibrinogen should additionally be administered in an average daily dose of 2-4 g (maximum dose of 8 g).

    Special instructions:

    In connection with the possibility of thromboembolic complications in the postpartum period, it is not appropriate to use aminocaproic acid to prevent bleeding during labor in women.

    With prolonged therapy, it is necessary to monitor the blood picture.

    It is not recommended to administer aminocaproic acid in hematuria due to the danger of developing acute renal failure.

    The purpose of the drug requires checking the fibrinolytic activity of blood and the concentration of fibrinogen in the blood. With intravenous administration, coagulogram monitoring is necessary, especially in coronary heart disease, after myocardial infarction, in pathological processes in the liver.

    Form release / dosage:

    Solution for infusions 50 mg / ml.

    Packaging:

    100 ml in glass bottles for blood, transfusion and infusion preparations with a capacity of 100 ml, corked with rubber stoppers and crimped with aluminum caps.Labels are put on bottles from paper of label or writing or from other paper in quality not lower than specified.

    Each bottle, along with instructions for medical use, is placed in a pack of cardboard for consumer packaging (for sale through the pharmacy network).

    It is allowed to put the text of the instruction for medical use on the pack in a typographical way.

    36 packs of bottles with a capacity of 100 ml are placed in a box of cardboard for consumer packaging or in a box of corrugated cardboard.

    For hospitals: 36 bottles with a capacity of 100 ml, together with instructions for medical use in quantities corresponding to the number of primary packages, are placed in a box of consumer paper containers with a cardboard padding or in a box of corrugated paper with gaskets and gratings (sockets).

    100 ml in polymer containers with a capacity of 100, 200 or 250 ml, into polymeric containers formed during production from a polyolefin film for the production of soft containers for infusion solutions, a three-layer coextrusive, or a film of polyethylene and a copolymer of propylene for the production of soft containers for infusion solutions ,a polyolefin / block copolymer bag or a single or separate tubular film and sealed with polycarbonate ports with a plug of gray rubber and a cap of aluminum and propylene to soft containers for infusion solutions or polypropylene ports (polypropylene container clogging systems) or polymeric containers Single-use polypropylene Siflex Pack with plug and adapter for infusion solutions, blood preservatives, blood substitutes, biological preparations and water for injection, or in containers EASURES polypropylene polymer for soft infusion solutions.

    On the surface of the container, text is applied or a label is applied from paper label or written or from other paper in quality not lower than indicated.

    To implement through the pharmacy network, each polymer container is packed in a bag of transparent polyethylene film.

    44 polymer containers with a capacity of 100 ml, 32 polymer containers with a capacity of 200 ml or 28 polymer containers with a capacity of 250 ml in bags of transparent polyethylene film or without bags (for hospitals) together with instructions for medical use and guidelines for the use of polymericcontainers with an infusion solution in an amount corresponding to the number of polymer containers are placed in a box of cardboard for consumer containers or in a box of corrugated cardboard.

    Storage conditions:

    In the dark place, in a vertical position (cork up) at a temperature of 0 to 25 ° C. Freezing of the drug is not allowed. Non-wetting of the inner surface of the bottle is not a contraindication to the use of the drug.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-003763/08
    Date of registration:16.05.2008 / 28.06.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:MOSFARM, OJSC MOSFARM, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp07.08.2017
    Illustrated instructions
      Instructions
      Up